セッション情報 |
パネルディスカッション15(消化器外科学会・消化器病学会・消化器内視鏡学会合同)
進行膵癌に対する集学的治療の標準化に向けて
|
タイトル |
PD15-基調講演1:Toward standard multidisciplinary treatment for advanced pancreatic cancer
|
演者 |
H. Friess(Department of Surgery, Klinikum rechts der Isar) |
共同演者 |
C. Michalski(Department of Surgery, Klinikum rechts der Isar) |
抄録 |
In resectable pancreatic cancer oncological resection followed by adjuvant chemotherapy is the standard of care in Europe. The key element in resectable pancreatic cancer is still oncological resection. Major improvements in surgery have contributed to a better outcome of pancreatic cancer patients. Standardization of surgery and ongoing centralisation of pancreatic surgery have much contributed to a significant reduction in postoperative morbidity and mortality. In centres for pancreatic surgery a morbidity rate lower than 5% and down to 2% is nowadays standard. In addition, patients operated in high volume centres have a significant longer survival compared to patients that were operative by surgeons with less experience. In addition, extension of the resection margins beyond the venous-portal system has contributed to higher resection rates and better survival.In addition, the introduction of standardized histopathological investigation of the resection specimens led to a better understanding of the clinical significance of a tumor free resection margin (R0). This contributes also to a better understanding of the surgeons where limitations towards a R0 resection still existMedical oncologists with specialisation in GIcancers are also important partners in the multidisciplinary therapy of pancreatic cancer. Adjuvant chemotherapy and the careful evaluation of new chemotherapeutics and biologicals are eminent to further improve survival of these patients.In summary, the close interdisciplinary interaction between gastroenterologists, surgeons, pathologists and medical oncologists is a mandatory to achieve further progress in the treatment of advanced pancreatic cancer. |
索引用語 |
pancreas, cancer |